Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Market Revenue to Attain USD 4.30 Bn by 2033

18 Jul 2025

Share :

Table of Content

1. Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Market Revenue and Trends 2025 to 2033 2. Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Market: Trends and Insights 3. Segment Outlook 4. Regional Insights 5. Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Market Coverage 6. Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Market Key Players

Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Market Revenue and Trends 2025 to 2033

The global veterinary analgesics/anti-inflammatory (NSAIDs) market revenue reached USD 2.59 billion in 2025 and is predicted to attain around USD 4.30 billion by 2033 with a CAGR of 6.54%. The growth of the market is driven by the increased awareness regarding animal health and rise in pet ownership worldwide. The rising production of livestock and commercialization of animal husbandry further contributes to market growth.

Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Market: Trends and Insights

The global market for veterinary analgesics/anti-inflammatory (NSAIDs) is experiencing robust growth, driven by increased pet ownership, greater awareness of animal welfare, and a rise in chronic pain and inflammatory conditions, mainly in companion and livestock animals. Enhanced veterinary healthcare, including improved diagnostics and treatment, has enabled earlier identification and treatment of painful disorders, increasing demand for effective analgesics. Furthermore, the growing number of surgical procedures and the need for associated post-operative care are also strengthening growth prospects.

Segment Outlook

• By drug class, the NSAID segment held the largest share of the market in 2024. This is due to its effectiveness, speed of action, and widespread use in alleviating pain and inflammation in various species.
• By animal type, the companion animals segment led the market in 2024. This is primarily due to the increased pet ownership rate across the globe. With the increased pet humanization, there is a significant rise in veterinary visits. Pet owners have become aware of the prevalence of pain-related conditions, boosting the demand for efficient pain management products for their pets.
• By route of administration, the oral segment dominated the veterinary analgesics/anti-inflammatory (NSAIDs) market in 2024. The segment’s dominance stems from its ease of administration, improved convenience, and improved patient compliance. Oral formulations are preferred for long-term pain management.
• By indication, the musculoskeletal disorders segment led the market in 2024, driven by the high prevalence of arthritis and joint problems among animals that require long-term and efficient anti-inflammatory pain management.
• By distribution channel, the veterinary clinics & hospitals segment maintained dominance in the market in 2024. This is due to the easy availability and accessibility of prescription as well as OTC NSAIDs. They are the trusted source and facilitate effective administration of medications, making them the preferred choice of pet owners for pain management of their pets.
• By end-user, the pet owners segment dominated the market in 2024 because of the increased concerns of pet health and wellness among pet owners, boosting the demand for effective pain management at home.

Regional Insights

North America dominated the veterinary analgesics and anti-inflammatory (NSAIDs) market, holding the largest share in 2024 due to its high pet ownership and advanced animal healthcare systems. The U.S. and Canada have maintained a stronghold in the market. This is due to the significant rise in the number of veterinary clinics over the past few years. Expansion of pet insurance further helps cover veterinary treatment costs, supporting market growth.

Asia Pacific is emerging as the fastest-growing market due to the rising production of livestock, driven by the increasing demand for dairy and meat products. The increasing pet adoption rate, combined with the availability of specialized veterinary services, particularly in China, India, and Japan, and the rising demand for a preventive treatment approach among farmers and pet owners, are expected to support market growth.

Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Market Coverage

Recent Developments

• In April 2025, Felixvet launched Carprofen Soft Chewable Tablets, a NSAID that is used to reduce pain and inflammation due to osteoarthritis and pain following surgery. These tablets are now available through animal health distributors.(Source: https://kcanimalhealth.thinkkc.com)

Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Market Key Players

• Zoetis Inc. 
• Boehringer Ingelheim Animal Health
• Elanco Animal Health
• Merck Animal Health (MSD Animal Health)
• Norbrook Laboratories
• Ceva Santé Animale
• Dechra Pharmaceuticals
• Vetoquinol
• Virbac
• Chanelle Pharma
• Phibro Animal Health
• Bimeda Animal Health
• Huvepharma
• Zydus Animal Health
• Ourofino Saúde Animal
• Ashish Life Science
• KRKA
• Kyoritsu Seiyaku
• Indian Immunologicals
• Neogen Corporation

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6421

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com|+1 804 441 9344